Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 18 of the 19 references it cites were found in a registry or an index.

Real‐world treatment patterns, outcomes, resource utilization and costs in treatment‐resistant major depressive disorder: PATTERN, a retrospective cohort study in Belgium

Open access
Gillain, B., Degraeve, G., Dreesen, T., De Bruecker, G., Buntinx, E., Beke, D., Kestens, C., Valassopoulou, E., Verhelst, F., Peeters, E., Pype, S., De Vos, C., Strens, D., Vandersmissen, I. · 2022 · PharmacoEconomics - Open

Abstract

OBJECTIVE: Treatment-resistant depression (TRD), a subgroup of major depressive disorder (MDD) that does not adequately respond to treatment, has a substantial impact on the quality of life of patients and is associated with higher medical and mental health care costs. This study aimed to report real-world treatment patterns, outcomes, resource utilization, and costs in the management of TRD by psychiatrists in Belgium. METHODS: We conducted a retrospective, non-interventional cohort study of patients ≥ 18 years, with diagnosed MDD who are treatment-resistant, defined as not responding to two different antidepressant treatments in the current moderate to severe major depressive episode (MDE). Data obtained from medical records of patients included patient health state (MDE, response, remission, and recovery) and resource use (number of consultations and emergency room visits, non-drug and drug interventions, and hospitalizations). RESULTS: One hundred and twenty-five patients were enrolled in nine sites, with an average observation period of 34 months. During the MDE, 89.7% of patients were treated with selective serotonin reuptake inhibitors, 63.2% with serotonin-norepinephrine reuptake inhibitors, and 60.8% with anti-psychotics. Twenty-four percent of patients did not respond to any treatment; 76% responded, of whom 61% experienced a relapse; 28% of patients reached recovery, of whom 31.4% experienced recurrence. The average yearly direct cost of a TRD patient is €9012, mainly driven by hospitalization in the MDE. The observed absenteeism relates to a high indirect cost, representing 70% of the total MDE cost. CONCLUSION: TRD is associated with a high unmet need and economic burden for patients and society, with highest costs in the MDE health state driven by absenteeism.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s41669-021-00306-2

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Average direct cost per TRD patient: per year (a) and per month by health state (b). MDE major depressive episode, TRD treatment-resistant depression. Details on the average direct cost per patient per month can be found in Supplementary Table 3 (ESM)
Fig. 1 Average direct cost per TRD patient: per year (a) and per month by health state (b). MDE major depressive episode, TRD treatment-resistant depression. Details on the average direct cost per patient per month can be found in Supplementary Table 3 (ESM)CC BY-NC · PubMed Central
Fig. 2 Monthly direct and indirect costs per health state. MDE major depressive episode
Fig. 2 Monthly direct and indirect costs per health state. MDE major depressive episodeCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Research works printed but not linked: 5

  1. Karakaya G. Evolutie van de prevalentie en de kostprijs van chronische ziektes. Onafhankelijke Ziekenfondsen; 2015.
  2. Greenwood M. A report on the natural duration of cancer. In: Reports on public health and medical subjects, vol. 33. London: His Majesty’s Stationery Office; 1926. pp. 1–26.
  3. APA. American Psychiatric Association: Practice Guideline For The Treatment of Patients With Major Depressive Disorder; 2010. 3rd Edition. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf Accessed 7 Mar 2021.
  4. N.I.C.E, National Institute for Health and Clinical Excellence: Guidance, in Depression: The Treatment and Management of Depression in Adults (Updated Edition). Leicester (UK): British Psychological Society; 2010.
  5. Umbach I, Vanrillaer V. Verblijven in een psychiatrische omgeving. Onafhankelijke Ziekenfondsen; 2014.

Cited by

See all 16

Metadata

Authors
Gillain, B., Degraeve, G., Dreesen, T., De Bruecker, G., Buntinx, E., Beke, D., Kestens, C., Valassopoulou, E., Verhelst, F., Peeters, E., Pype, S., De Vos, C., Strens, D., & Vandersmissen, I.
Affiliations
  • Clinique Saint Pierre (BE)
  • Alma (BE)
  • Centre Hospitalier Régional de Huy (BE)
  • Centre hospitalier régional de la Citadelle (BE)
  • Grand Charleroi Hospital (BE)
  • Janssen (Belgium) (BE)
Corresponding author
Vandersmissen, I.
Venue
PharmacoEconomics - Open
Published
2021-11-15
Volume
6
Issue
2
Pages
293-302
ISSN
  • 2509-4254 (ISSN-L)
  • 2509-4262
OpenAlex
W3211811847
Cited by
16
References
19
Citations by year
2026: 2 · 2025: 2 · 2024: 2 · 2023: 8 · 2022: 1 · 2021: 1
FWCI
1.75
Type
journal article
Language
en
Open access
Licence
Locations
  • PharmacoEconomics - Open (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
Keywords
treatment-resistant depression, major depressive disorder, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, antipsychotic drugs, treatment response and remission, relapse, hospitalization, health care costs, absenteeism, economic burden, Belgium

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Real‐world treatment patterns, outcomes, resource utilization and costs in treatment‐resistant major depressive disorder: PATTERN, a retrospective cohort study in Belgium. https://app.cochat.ai/papers/10.1007/s41669-021-00306-2
The paper
Gillain, B., Degraeve, G., Dreesen, T., De Bruecker, G., Buntinx, E., Beke, D., Kestens, C., Valassopoulou, E., Verhelst, F., Peeters, E., Pype, S., De Vos, C., Strens, D., & Vandersmissen, I. (2022). Real‐world treatment patterns, outcomes, resource utilization and costs in treatment‐resistant major depressive disorder: PATTERN, a retrospective cohort study in Belgium. PharmacoEconomics - Open. https://doi.org/10.1007/s41669-021-00306-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.